HK1048070A1 - 选择性pde10抑制物的治疗用途 - Google Patents

选择性pde10抑制物的治疗用途 Download PDF

Info

Publication number
HK1048070A1
HK1048070A1 HK03100308.4A HK03100308A HK1048070A1 HK 1048070 A1 HK1048070 A1 HK 1048070A1 HK 03100308 A HK03100308 A HK 03100308A HK 1048070 A1 HK1048070 A1 HK 1048070A1
Authority
HK
Hong Kong
Prior art keywords
disorder
disease
disorders
mammal
papaverine
Prior art date
Application number
HK03100308.4A
Other languages
English (en)
Chinese (zh)
Inventor
洛兰‧A‧莱博尔
洛蘭‧A‧萊博爾
弗兰克‧S‧门尼蒂
克里斯托弗‧J‧施米特
弗蘭克‧S‧門尼蒂
Original Assignee
辉瑞产品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23092939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1048070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 辉瑞产品公司 filed Critical 辉瑞产品公司
Publication of HK1048070A1 publication Critical patent/HK1048070A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100308.4A 2001-04-20 2003-01-14 选择性pde10抑制物的治疗用途 HK1048070A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28514801P 2001-04-20 2001-04-20
US60/285,148 2001-04-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK06112416.5A Division HK1091746A (en) 2001-04-20 2003-01-14 Therapeutic use of selective pde10 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK06112416.5A Addition HK1091746A (en) 2001-04-20 2003-01-14 Therapeutic use of selective pde10 inhibitors

Publications (1)

Publication Number Publication Date
HK1048070A1 true HK1048070A1 (zh) 2003-03-21

Family

ID=23092939

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100308.4A HK1048070A1 (zh) 2001-04-20 2003-01-14 选择性pde10抑制物的治疗用途

Country Status (13)

Country Link
US (1) US20030008806A1 (enExample)
EP (1) EP1250923A3 (enExample)
JP (1) JP3839343B2 (enExample)
KR (2) KR20020082136A (enExample)
CN (2) CN1382490A (enExample)
AU (1) AU3440902A (enExample)
CA (1) CA2382326A1 (enExample)
HK (1) HK1048070A1 (enExample)
HU (1) HUP0201310A3 (enExample)
IL (1) IL149106A0 (enExample)
NZ (1) NZ518478A (enExample)
PL (1) PL353535A1 (enExample)
ZA (1) ZA200203123B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US20060110783A1 (en) * 2002-11-08 2006-05-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
EP1562588A4 (en) * 2002-11-15 2007-10-31 Merck & Co Inc USE OF PDE4 INHIBITORS AS ADDITIONAL TREATMENT IN PSYCHIATRICAL DISEASES
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
MXPA05013553A (es) * 2003-06-30 2006-03-09 Altana Pharma Ag Pirrolodihidroisoquinolinas como inhibidores de pde10.
EP1641457B1 (en) * 2003-06-30 2009-08-05 Nycomed GmbH Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
BRPI0511854A (pt) * 2004-06-07 2008-01-15 Pfizer Prod Inc inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
DE602006006544D1 (de) * 2005-01-12 2009-06-10 Nycomed Gmbh Neue pyrrolodihydroisochinoline als pde10-inhibitoren
EP1940819A1 (en) * 2005-08-16 2008-07-09 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
CA2661992A1 (en) * 2006-09-06 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
EP2348018A4 (en) 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
EP2351748A4 (en) 2008-10-09 2012-03-21 Kyorin Seiyaku Kk ISOCHINOLINE DERIVATIVES AND THESE PDE INHIBITORS CONTAINING ACTIVE SUBSTANCE
PT2443105E (pt) 2009-06-19 2015-01-14 Lundbeck & Co As H Novo derivado de fenilimidazole como inibidor da enzima pde10a
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
PH12012501643A1 (en) 2010-02-26 2017-07-19 Mitsubishi Tanabe Pharma Corp Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
TR201904614T4 (en) 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
JP3276762B2 (ja) * 1993-12-28 2002-04-22 日本臓器製薬株式会社 イソキノリン誘導体を含有する医薬組成物
HUT71408A (en) * 1994-01-14 1995-11-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission
FI964113L (fi) * 1994-04-15 1996-10-14 Iyo Masaomi Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
WO1997027745A1 (en) * 1996-01-31 1997-08-07 Technology Licensing Co. L.L.C. Method of diagnosis and treatment and related compositions and apparatus
KR0177295B1 (ko) * 1996-02-28 1999-03-20 정명식 이소퀴놀린 화합물을 함유하는 항우울제
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
EP1060251B1 (en) * 1998-02-23 2006-06-28 ICOS Corporation Phosphodiesterase 10
AU775102B2 (en) * 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame

Also Published As

Publication number Publication date
ZA200203123B (en) 2003-10-20
PL353535A1 (en) 2002-10-21
HUP0201310A2 (hu) 2003-02-28
CN1382490A (zh) 2002-12-04
EP1250923A2 (en) 2002-10-23
AU3440902A (en) 2002-10-24
CN1840181A (zh) 2006-10-04
JP2002363103A (ja) 2002-12-18
HUP0201310A3 (en) 2008-10-28
US20030008806A1 (en) 2003-01-09
HU0201310D0 (enExample) 2002-06-29
JP3839343B2 (ja) 2006-11-01
KR20020082136A (ko) 2002-10-30
CA2382326A1 (en) 2002-10-20
KR20060002003A (ko) 2006-01-06
EP1250923A3 (en) 2003-01-15
NZ518478A (en) 2004-04-30
IL149106A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
JP3839343B2 (ja) 選択的ｐｄｅ１０阻害剤の治療的使用
RU2303259C2 (ru) Терапевтическое применение селективных ингибиторов pde10
Xu et al. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders
Li et al. Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia
Bollen et al. Phosphodiesterases in neurodegenerative disorders
Van Staveren et al. mRNA expression patterns of the cGMP‐hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain
Jankowska et al. PDE7-selective and dual inhibitors: advances in chemical and biological research
J. Titus et al. Phosphodiesterase inhibitors as therapeutics for traumatic brain injury
Wennogle et al. Phosphodiesterase 1: a unique drug target for degenerative diseases and cognitive dysfunction
US20030018047A1 (en) Therapeutic use of selective PDE10 inhibitors
Vidal et al. Decreasing the expression of GABAA α5 subunit-containing receptors partially improves cognitive, electrophysiological, and morphological hippocampal defects in the Ts65Dn model of Down syndrome
HK1091746A (en) Therapeutic use of selective pde10 inhibitors
EP1666886A2 (en) Method of identifying selective PDE10 inhibitor compounds
Gross-Isseroff et al. Unaltered α2-noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysis
Matthews et al. Complex genetics of interactions of alcohol and CNS function and behavior
Siuciak et al. Treating neuropsychiatric disorders with PDE10A inhibitors
AU2007200574A1 (en) Therapeutic use of selective PDE10 inhibitors
Brandon et al. Cyclic-nucleotide phosphodiesterases in the central nervous system: from biology to drug discovery
HK1077331A (en) Therapeutic use of selective pde10 inhibitors
ZA200407823B (en) Therapeutic use of selective PDE10 inhibitors
EP1325335B1 (en) Methods for diagnosing and treating huntington's disease
Menniti et al. Pharmacological manipulation of cyclic nucleotide phosphodiesterase signaling for the treatment of neurological and psychiatric disorders in the brain
Laprairie et al. Alterations in expression and function of phosphodiesterases in Huntington’s disease
Zhang Neuropsychopharmacological Effects of Selective Inhibitors of Subtypes of Phosphodiesterase-4 in Mice